SEC Form 4 · accession 0001209191-18-002988
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Glenning
Director
Period of report
Jan 7, 2018
Accepted (ET)
Jan 9, 2018 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $59.14 | Jan 7, 2018 | A | 10,000 | A | — | Jan 6, 2028 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option fully vests on January 7, 2019, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.